The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
Sumitomo Charts Revival Plan, Eyes 250 Billion Yen with 3 Key Meds by FY2027
To read the full story
BUSINESS
- Japan Vaccine Market to Reach 297 Billion Yen in FY2025: Fuji Keizai
June 13, 2025
- SanBio Inches Closer to Cell Therapy Shipment with Partial Change Filing
June 13, 2025
- Nippon Chemiphar to Launch Amaryl AGs on June 20
June 13, 2025
- Takeda’s Livmarli, HyQvia Now Available in Japan
June 13, 2025
- Boehringer Files Nerandomilast for Pulmonary Fibrosis in Japan
June 13, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…